Management of potentially resectable colorectal cancer liver metastases

Table 1 European Organization for Research and Treatment of Cancer 40983 Trial

	n	Treatment	HR for progression	3-yr PFS	5-yr PFS	Postoperative OS complications
All pts	364	CHT	0.79	35.4	51.2	-
		Surgery alone	P = 0.058	28.1	47.8 (P = 0.339)	-
Elegible pts	342	CHT	0.77	36.2	52.4	-
		Surgery alone	P = 0.041	28.1	48.3 (P = 0.303)	-
Resected pts	329	CHT	0.73	42.4		25%
		Surgery alone	P = 0.025	33.2		16%

Reproduced from reference Nordlinger et al[22] and Sorbye et al[23]. pts: Patients; CHT: Chemotherapy; HR: Hazard ratio; PFS: Progression free survival; OS: Overall survival.

Table 2 Phase III trials of adjuvant chemotherapy after resection of colorectal liver metastases

Ref	n	CHT	Median PFS (mo)	Median OS (mo)
Langer et al[26]	129	5-FU/LV	No difference	No difference
Portier et al[27]	173	5-FU/LV	24.4 vs 16.6 (P = 0.028)	62.1 vs 46.4 (P = 0.13)
Mitry et al[28]	278	5-FU/LV	27.9 vs 18.8 (P = 0.059)	61.1 vs 46.9 (P = 0.125)
Ychou et al[31]	306	FOLFIRI vs 5-FU/LV	24.7 vs 21.6 (P = 0.44)	No difference

CHT: Chemotherapy; PFS: Progression free survival; OS: Overall survival; 5-FU/LV: 5-fluorouracil/Leucovorin; FOLFIRI: 5-FU/LV/Irinotecan.